Is BNTX stock today in an uptrend?

Yes. Price sits above the 50-day at 99.39 and 200-day at 103.12 on the ADR, with RSI near 61 and a positive MACD histogram. That supports a constructive trend, though CCI and MFI suggest it is near overbought. Pullbacks can occur before the next leg higher.

What are the top BioNTech oncology catalysts for 2026?

Focus on BNT113 in HPV+ head and neck cancer, BNT111 in melanoma, and BNT122 in personalized neoantigen therapy. Multiple late-stage updates are expected in 2026. Positive data or regulatory progress could affect valuation quickly, making BNTX stock today sensitive to these milestones.

How does the FDA accelerated pathway impact BNT113?

The FDA accelerated pathway may shorten time to a potential approval if study endpoints are met and confirmatory data follow. It brings earlier access to promising therapies while maintaining post-approval evidence needs. For BNTX stock today, each BNT113 update can influence sentiment and near-term price action.

What price levels matter for traders right now?

On the ADR, watch support near the 200-day at $103 and resistance around $124 and $126.77. On Xetra, EUR 100 is a key sentiment line after the EUR 99.40 six-month high. For BNTX stock today, momentum holds if price stays above these supports on closing basis.

Global Market Insights

BNTX Stock Today: January 23 momentum after six-month high, 2026 catalysts

ByHuzaifa Zahoor January 23, 2026

BNTX stock today is drawing fresh attention in Germany after BNTX hit a six-month high at EUR 99.40 on 21 January and held gains into 23 January. Momentum aligns with a Goldman Sachs upgrade to Buy and a $142 target, an FDA accelerated pathway for BNT113, and a busy 2026 oncology slate. The ADR trades above its 50-day and 200-day averages, signaling improving sentiment. We break down price action, catalysts, valuation, and practical steps for local investors.